<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="ced" content-type="chapter" from-where="body" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">gene</book-id>
    <book-title-group>
      <book-title>GeneReviews<sup>&#x000ae;</sup></book-title>
    </book-title-group>
    <contrib-group>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Adam</surname>
          <given-names>Margaret P</given-names>
        </name>
        <role>Editor-in-Chief</role>
      </contrib>
    </contrib-group>
    <contrib-group>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Ardinger</surname>
          <given-names>Holly H</given-names>
        </name>
      </contrib>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Pagon</surname>
          <given-names>Roberta A</given-names>
        </name>
      </contrib>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Wallace</surname>
          <given-names>Stephanie E</given-names>
        </name>
      </contrib>
      <role>Senior Editors</role>
    </contrib-group>
    <contrib-group>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Bean</surname>
          <given-names>Lora JH</given-names>
        </name>
      </contrib>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Mefford</surname>
          <given-names>Heather C</given-names>
        </name>
      </contrib>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Stephens</surname>
          <given-names>Karen</given-names>
        </name>
      </contrib>
      <role>Molecular Genetics</role>
    </contrib-group>
    <contrib-group>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Amemiya</surname>
          <given-names>Anne</given-names>
        </name>
      </contrib>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Ledbetter</surname>
          <given-names>Nikki</given-names>
        </name>
      </contrib>
      <role>Genetic Counseling</role>
    </contrib-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <year>1993</year>
    </pub-date>
    <pub-date publication-format="electronic" date-type="pubr">
      <year>2017</year>
    </pub-date>
    <issn>2372-0697</issn>
    <publisher>
      <publisher-name>University of Washington, Seattle</publisher-name>
      <publisher-loc>Seattle (WA)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 1993-2017, University of Washington, Seattle. GeneReviews is a registered trademark of the University of Washington, Seattle. All rights reserved.</copyright-statement>
      <copyright-year>2017</copyright-year>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://www.ncbi.nlm.nih.gov/books/NBK138602/">
        <license-p>GeneReviews&#x000ae; chapters are owned by the University of Washington. Permission is hereby granted to reproduce, distribute, and translate copies of content materials for noncommercial research purposes only, provided that (i) credit for source (<ext-link ext-link-type="uri" xlink:href="http://www.genereviews.org/">http://www.genereviews.org/</ext-link>) and copyright (&#x000a9; 1993-2017 University of Washington) are included with each copy; (ii) a link to the original material is provided whenever the material is published elsewhere on the Web; and (iii) reproducers, distributors, and/or translators comply with the <related-object source-id="gene" document-id="GRcopyright_permiss">GeneReviews&#x000ae; Copyright Notice and Usage Disclaimer</related-object>. No further modifications are allowed. For clarity, excerpts of GeneReviews chapters for use in lab reports and clinic notes are a permitted use.</license-p>
        <license-p>For more information, see the <related-object source-id="gene" document-id="GRcopyright_permiss">GeneReviews&#x000ae; Copyright Notice and Usage Disclaimer</related-object>.</license-p>
        <license-p>For questions regarding permissions or whether a specified use is allowed, contact: <email>admasst@uw.edu</email>.</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-subject</meta-name>
        <meta-value>Genetics</meta-value>
      </custom-meta>
      <custom-meta>
        <meta-name>books-subject</meta-name>
        <meta-value>Medicine</meta-value>
      </custom-meta>
      <custom-meta>
        <meta-name>books-subject</meta-name>
        <meta-value>Diseases</meta-value>
      </custom-meta>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="ednotes">
      <p content-type="genetic_counseling">
<italic toggle="yes">Genetic counseling is the process of
providing individuals and families with information on the nature, inheritance,
and implications of genetic disorders to help them make informed medical and
personal decisions. The following section deals with genetic risk assessment and
the use of family history and genetic testing to clarify genetic status for
family members. This section is not meant to address all personal, cultural, or
ethical issues that individuals may face or to substitute for consultation with
a genetics professional</italic>. &#x02014;ED.</p>
      <p content-type="resources">
<italic toggle="yes">GeneReviews staff has selected the following disease-specific and/or
umbrella support organizations and/or registries for the benefit of individuals
with this disorder and their families. GeneReviews is not responsible for the
information provided by other organizations. For information on selection
criteria, click <related-object source-id="gene" document-id="app4">here</related-object>.</italic></p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <book-part-id book-part-id-type="pmcid">ced</book-part-id>
      <title-group>
        <title>Camurati-Engelmann Disease</title>
        <alt-title alt-title-type="alt-title">Synonym: Progressive Diaphyseal Dysplasia </alt-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Wallace</surname>
            <given-names>Stephanie E</given-names>
          </name>
          <degrees>MD</degrees>
          <email>stephanie.wallace@seattlechildrens.org</email>
          <aff>Division of Genetic Medicine<break/>University of Washington<break/>Seattle Children&#x02019;s Hospital<break/>Seattle, Washington</aff>
        </contrib>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Wilcox</surname>
            <given-names>William R</given-names>
          </name>
          <degrees>MD, PhD</degrees>
          <email>william.wilcox@emory.edu</email>
          <aff>Department of Human Genetics<break/>Emory University School of Medicine<break/>Atlanta, Georgia</aff>
        </contrib>
      </contrib-group>
      <pub-history>
        <date iso-8601-date="2004-06-25" date-type="created">
          <day>25</day>
          <month>6</month>
          <year>2004</year>
        </date>
        <date iso-8601-date="2015-03-05" date-type="updated">
          <day>5</day>
          <month>3</month>
          <year>2015</year>
        </date>
      </pub-history>
      <related-object link-type="parent-book-link" source-id="gene">GeneReviews<sup>&#x000ae;</sup></related-object>
      <related-object link-type="previous-part-link" source-id="gene" document-id="campo-dysp" document-type="chapter">Campomelic Dysplasia</related-object>
      <related-object link-type="next-part-link" source-id="gene" document-id="canavan" document-type="chapter">Canavan Disease</related-object>
      <abstract id="ced.Summary">
        <title>Summary</title>
        <sec>
          <title>Clinical characteristics</title>
          <p>Camurati-Engelmann disease (CED) is characterized by hyperostosis of the long bones and the skull, proximal muscle weakness, severe limb pain, a wide-based, waddling gait, and joint contractures. Facial features such as frontal bossing, enlargement of the mandible, proptosis, and cranial nerve impingement resulting in facial palsy are seen in severely affected individuals later in life. </p>
        </sec>
        <sec>
          <title>Diagnosis/testing</title>
          <p>Diagnosis of CED is based on physical examination and radiographic findings and can be confirmed by identification of a heterozygous pathogenic variant in <italic toggle="yes">TGFB1</italic> on molecular genetic testing. </p>
        </sec>
        <sec>
          <title>Management</title>
          <p><italic toggle="yes">Treatment of manifestations:</italic> Treatment includes use of corticosteroids to control pain. Losartan may be a helpful adjuvant therapy to minimize the need for steroids to control pain. Pain is also managed with analgesics and non-pharmacologic methods. Bilateral myringotomy can improve conductive hearing loss resulting from serous otitis. </p>
          <p><italic toggle="yes">Surveillance:</italic> Following initiation of corticosteroid treatment, blood pressure should be monitored monthly; when maintenance steroid dose is achieved, yearly evaluation includes complete neurologic examination, CBC, blood pressure, hearing screen, and bone density scan.</p>
        </sec>
        <sec>
          <title>Genetic counseling</title>
          <p>CED is inherited in an autosomal dominant manner. Penetrance is reduced. The incidence of <italic toggle="yes">de novo</italic> mutation is unknown. Each child of an individual with CED has a 50% chance of inheriting the <italic toggle="yes">TGFB1</italic> pathogenic variant. Prenatal diagnosis for pregnancies at increased risk is possible for families in which the pathogenic variant has been identified. </p>
        </sec>
      </abstract>
    </book-part-meta>
    <body>
      <sec id="ced.GeneReview_Scope">
        <title><italic toggle="yes">GeneReview</italic> Scope</title>
        <table-wrap id="ced.Tc" position="anchor" orientation="portrait">
          <table frame="hsides" rules="groups">
            <thead>
              <tr>
                <th id="hd_h_ced.Tc_1_1_1_1" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Camurati-Engelmann Disease: Included Disorders</th>
              </tr>
            </thead>
            <tbody>
              <tr>
                <td headers="hd_h_ced.Tc_1_1_1_1" valign="middle" align="left" rowspan="1" colspan="1">
                  <list list-type="bullet">
                    <list-item>
                      <p>Ribbing disease</p>
                    </list-item>
                  </list>
                </td>
              </tr>
            </tbody>
          </table>
          <table-wrap-foot>
            <fn>
              <p>For synonyms and outdated names see <xref ref-type="sec" rid="ced.Nomenclature">Nomenclature</xref>.</p>
            </fn>
          </table-wrap-foot>
        </table-wrap>
      </sec>
      <sec id="ced.Diagnosis">
        <title>Diagnosis</title>
        <p>There are no current published guidelines for the diagnosis of Camurati-Engelmann disease.</p>
        <sec id="ced.Suggestive_Findings">
          <title>Suggestive Findings</title>
          <p>Camurati-Engelmann disease (CED) should be suspected in individuals with the following clinical findings:</p>
          <list list-type="bullet">
            <list-item>
              <p>Proximal muscle weakness</p>
            </list-item>
            <list-item>
              <p>Limb pain</p>
            </list-item>
            <list-item>
              <p>Waddling gait</p>
            </list-item>
          </list>
        </sec>
        <sec id="ced.Establishing_the_Diagnosis">
          <title>Establishing the Diagnosis</title>
          <p>The diagnosis of CED is established in a proband with the characteristic radiographic findings or by molecular genetic testing (<xref ref-type="table" rid="ced.T.summary_of_molecular_genetic_testi">Table 1</xref>) if radiographic findings are inconclusive.</p>
          <p>
            <bold>Radiographic findings</bold>
          </p>
          <list list-type="bullet">
            <list-item>
              <p>Hyperostosis of one or more of the long bones: </p>
              <list list-type="bullet">
                <list-item>
                  <p>Begins with the diaphyses of the long bones</p>
                </list-item>
                <list-item>
                  <p>Can progress to the metaphyses and rarely epiphyses</p>
                </list-item>
              </list>
            </list-item>
            <list-item>
              <p>Periosteal involvement with uneven cortical thickening and increased diameter</p>
            </list-item>
            <list-item>
              <p>Endosteal bony sclerosis that can lead to narrowed medullary canal</p>
            </list-item>
            <list-item>
              <p>Usually symmetric in the appendicular skeleton but may be asymmetricNote: Hyperostosis does not affect the spine.</p>
            </list-item>
            <list-item>
              <p>Other radiologic findings variably seen: </p>
              <list list-type="bullet">
                <list-item>
                  <p>Skull involvement beginning at the base of the anterior and middle fossae and often including the frontal bone [<xref ref-type="bibr" rid="ced.REF.wallace.2004.235">Wallace et al 2004</xref>] </p>
                </list-item>
                <list-item>
                  <p>Mild osteosclerosis in the posterior neural arch of the spine and parts of the flat bones that correspond to the diaphysis</p>
                </list-item>
              </list>
            </list-item>
          </list>
          <p><bold>Molecular genetic testing</bold> approaches can include:</p>
          <list list-type="bullet">
            <list-item>
              <p>Sequence analysis of <italic toggle="yes">TGFB1.</italic> Deletion/duplication analysis is available. However, no deletions or duplications have been reported thus far. </p>
            </list-item>
            <list-item>
              <p>Use of a multi-gene panel that includes <italic toggle="yes">TGFB1</italic> and other genes of interest (see <xref ref-type="sec" rid="ced.Differential_Diagnosis">Differential Diagnosis</xref>). Note: The genes included and the methods used in multi-gene panels vary by laboratory and over time. </p>
            </list-item>
          </list>
          <table-wrap id="ced.T.summary_of_molecular_genetic_testi" position="anchor" orientation="portrait">
            <label>Table 1. </label>
            <caption>
              <p>Summary of Molecular Genetic Testing Used in Camurati-Engelmann Disease</p>
            </caption>
            <table frame="hsides" rules="groups">
              <thead>
                <tr>
                  <th id="hd_h_ced.T.summary_of_molecular_genetic_testi_1_1_1_1" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Gene&#x000a0;<sup>1</sup></th>
                  <th id="hd_h_ced.T.summary_of_molecular_genetic_testi_1_1_1_2" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Test Method</th>
                  <th id="hd_h_ced.T.summary_of_molecular_genetic_testi_1_1_1_3" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Proportion of Probands with a Pathogenic Variant Detectable by This Method</th>
                </tr>
              </thead>
              <tbody>
                <tr>
                  <td headers="hd_h_ced.T.summary_of_molecular_genetic_testi_1_1_1_1" rowspan="2" valign="middle" align="left" scope="row" colspan="1">
                    <italic toggle="yes">TGFB1</italic>
                  </td>
                  <td headers="hd_h_ced.T.summary_of_molecular_genetic_testi_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">Sequence analysis&#x000a0;<sup>2</sup>
</td>
                  <td headers="hd_h_ced.T.summary_of_molecular_genetic_testi_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">&#x0003e;90%&#x000a0;<sup>3</sup></td>
                </tr>
                <tr>
                  <td headers="hd_h_ced.T.summary_of_molecular_genetic_testi_1_1_1_2" valign="middle" colspan="1" align="left" scope="row" rowspan="1">Deletion/duplication analysis&#x000a0;<sup>4</sup></td>
                  <td headers="hd_h_ced.T.summary_of_molecular_genetic_testi_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">Unknown, none reported</td>
                </tr>
                <tr>
                  <td headers="hd_h_ced.T.summary_of_molecular_genetic_testi_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">Unknown&#x000a0;<sup>5</sup></td>
                  <td headers="hd_h_ced.T.summary_of_molecular_genetic_testi_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">NA</td>
                  <td headers="hd_h_ced.T.summary_of_molecular_genetic_testi_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1"/>
                </tr>
              </tbody>
            </table>
            <table-wrap-foot>
              <fn>
                <p>NA = not applicable</p>
              </fn>
              <fn id="ced.TF.1.1">
                <label>1. </label>
                <p>See <related-object source-id="gene" document-id="ced" object-id="ced.molgen.TA">Table A. Genes and Databases</related-object> for chromosome locus and protein. See <xref ref-type="sec" rid="ced.Molecular_Genetics">Molecular Genetics</xref> for information on allelic variants detected in this gene. </p>
              </fn>
              <fn id="ced.TF.1.2">
                <label>2. </label>
                <p>Sequence analysis detects variants that are benign, likely benign, of unknown significance, likely pathogenic, or pathogenic. Pathogenic variants may include small intragenic deletions/insertions and missense, nonsense, and splice site variants; typically, exonic or whole-gene deletions/duplications are not detected. For issues to consider in interpretation of sequence analysis results, click <related-object link-type="booklink" source-id="gene" document-id="app2" document-type="appendix">here</related-object>.</p>
              </fn>
              <fn id="ced.TF.1.3">
                <label>3. </label>
                <p>The majority are missense mutations in exon 4 leading to single amino acid substitutions in the encoded protein [<xref ref-type="bibr" rid="ced.REF.janssens.2000.273">Janssens et al 2000</xref>, <xref ref-type="bibr" rid="ced.REF.kinoshita.2000.19">Kinoshita et al 2000</xref>, <xref ref-type="bibr" rid="ced.REF.camposxavier.2001.653">Campos-Xavier et al 2001</xref>, <xref ref-type="bibr" rid="ced.REF.hecht.2001.198">Hecht et al 2001</xref>, <xref ref-type="bibr" rid="ced.REF.mumm.2001.593">Mumm et al 2001</xref>, <xref ref-type="bibr" rid="ced.REF.janssens.2003.7718">Janssens et al 2003</xref>, <xref ref-type="bibr" rid="ced.REF.kinoshita.2004.104">Kinoshita et al 2004</xref>, <xref ref-type="bibr" rid="ced.REF.wallace.2004.235">Wallace et al 2004</xref>, <xref ref-type="bibr" rid="ced.REF.janssens.2006.1">Janssens et al 2006</xref>]. </p>
              </fn>
              <fn id="ced.TF.1.4">
                <label>4. </label>
                <p>Testing that identifies exonic or whole-gene deletions/duplications not detectable by sequence analysis of the coding and flanking intronic regions of genomic DNA. Included in the variety of methods that may be used are: quantitative PCR, long-range PCR, multiplex ligation-dependent probe amplification (MLPA), and chromosomal microarray (CMA) that includes this gene/chromosome segment.</p>
              </fn>
              <fn id="ced.TF.1.5">
                <label>5. </label>
                <p>The affected members of one family with CED did not share marker haplotypes at the <italic toggle="yes">TGFB1</italic> locus and had no sequence alterations in <italic toggle="yes">TGFB1</italic> exons 1 through 7 [<xref ref-type="bibr" rid="ced.REF.hecht.2001.198">Hecht et al 2001</xref>]. Several additional individuals with CED have not had <italic toggle="yes">TGFB1</italic> pathogenic variants identified, implying genetic locus heterogeneity [Author, personal observation].</p>
              </fn>
            </table-wrap-foot>
          </table-wrap>
        </sec>
      </sec>
      <sec id="ced.Clinical_Description">
        <title>Clinical Characteristics</title>
        <sec id="ced.Natural_History">
          <title>Clinical Description</title>
          <p>Individuals with Camurati-Engelmann disease (CED) present with limb pain, proximal muscle weakness, poor muscular development, a wide-based, waddling gait, easy fatigability, and headaches. The average age of onset of symptoms in the 306 reported individuals is 13.4 years [<xref ref-type="bibr" rid="ced.REF.carlson.2010.566">Carlson et al 2010</xref>] with a range of birth to age 76 years [<xref ref-type="bibr" rid="ced.REF.wallace.2004.235">Wallace et al 2004</xref>]. </p>
          <p><bold>Musculoskeletal.</bold> Decreased muscle mass and weakness are most apparent in the proximal lower limbs, resulting in difficulty when rising from a sitting position. A wide-based, waddling gait is found in 64% of individuals. Joint contractures occur in 43% of individuals. Marfanoid body habitus is described in some affected individuals [<xref ref-type="bibr" rid="ced.REF.wallace.2004.235">Wallace et al 2004</xref>, <xref ref-type="bibr" rid="ced.REF.janssens.2006.1">Janssens et al 2006</xref>].Musculoskeletal involvement can lead to varying degrees of lumbar lordosis, kyphosis, scoliosis, coxae valga, genua valga, flat feet, and frontal bossing.</p>
          <p>Bone pain is reported in 90% of affected individuals [<xref ref-type="bibr" rid="ced.REF.wallace.2004.235">Wallace et al 2004</xref>, <xref ref-type="bibr" rid="ced.REF.janssens.2006.1">Janssens et al 2006</xref>]. The pain is described as constant, aching, and most intense in the lower limbs. Pain often increases with activity, stress, and cold weather. Many individuals have intermittent episodes of severe pain and incapacitation. The enlarged bone shafts can also be palpable and tender on examination; 52% of affected individuals report bone tenderness with palpation [<xref ref-type="bibr" rid="ced.REF.wallace.2004.235">Wallace et al 2004</xref>]. Intermittent limb swelling, erythema, and warmth also occur. </p>
          <p>Susceptibility to fracture may be reduced because of increased bone mineral density, but healing of fractures, when they occur, may be delayed [<xref ref-type="bibr" rid="ced.REF.wallace.2004.235">Wallace et al 2004</xref>]. </p>
          <p><bold>Neurologic.</bold> Sclerosis of the cranial nerve foramina can lead to direct nerve compression or neurovascular compromise. Cranial nerve deficits occur in 38% of affected individuals. The most common deficits are hearing loss, vision problems, and facial paralysis. </p>
          <p>Approximately 19% of individuals with CED have conductive and/or sensorineural hearing loss [<xref ref-type="bibr" rid="ced.REF.carlson.2010.566">Carlson et al 2010</xref>]. Conductive loss can be caused by narrowing of the external auditory meatus, bony encroachment of the ossicles, or narrowing of the oval and round windows. Sensorineural hearing loss is caused by narrowing of the internal auditory canal and compression of the cochlear nerve and/or vasculature. Sensorineural loss can also occur with attempted decompression of the facial nerves.</p>
          <p>Involvement of the orbit has led to blurred vision, proptosis, papilledema, epiphora, glaucoma, and subluxation of the globe [<xref ref-type="bibr" rid="ced.REF.carlson.2010.566">Carlson et al 2010</xref>]. </p>
          <p>Rarely, clonus [<xref ref-type="bibr" rid="ced.REF.neuhauser.1948.11">Neuhauser et al 1948</xref>], sensory loss, slurred speech, dysphagia, cerebellar ataxia, and bowel and bladder incontinence are reported [<xref ref-type="bibr" rid="ced.REF.carlson.2010.566">Carlson et al 2010</xref>]. Calvarial hyperostosis can lead to increased intracranial pressure and headaches. </p>
          <p><bold>Ribbing disease,</bold> an osteosclerotic disease of the long bones that is radiographically indistinguishable from CED and usually presents with bone pain after puberty [<xref ref-type="bibr" rid="ced.REF.makita.2000.153">Makita et al 2000</xref>], is now known to be caused by pathogenic variants in <italic toggle="yes">TGFB1</italic> [<xref ref-type="bibr" rid="ced.REF.janssens.2006.1">Janssens et al 2006</xref>]. Thus, CED and Ribbing disease represent phenotypic variations of the same disorder. </p>
          <p><bold>Other.</bold> Rare manifestations include anemia (hypothesized to be caused by a narrowed medullary cavity), anorexia, hepatosplenomegaly, decreased subcutaneous tissue, atrophic skin, hyperhidrosis of the hands and feet, delayed dentition, extensive caries, delayed puberty, and hypogonadism [<xref ref-type="bibr" rid="ced.REF.gupta.2005.399">Gupta &#x00026; Cheikh 2005</xref>].</p>
          <p><bold>Pregnancy.</bold> One individual who experienced relief with steroids also experienced decreased bone pain and improved muscle strength while pregnant, which allowed discontinuation of her steroid therapy. Scintigraphic bone imaging with MDP a few hours after delivery of her second child showed decreased uptake compared to imaging prior to pregnancy and six weeks post partum. </p>
        </sec>
        <sec id="ced.GenotypePhenotype_Correlations">
          <title>Genotype-Phenotype Correlations</title>
          <p>No known correlation exists between the nature of the <italic toggle="yes">TGFB1</italic> pathogenic variants and the severity of the clinical or radiographic manifestations [<xref ref-type="bibr" rid="ced.REF.camposxavier.2001.653">Campos-Xavier et al 2001</xref>]. </p>
        </sec>
        <sec id="ced.Penetrance">
          <title>Penetrance</title>
          <p>Some obligate heterozygotes with an identified <italic toggle="yes">TGFB1</italic> variant have had normal radiographs [<xref ref-type="bibr" rid="ced.REF.wallace.2004.235">Wallace et al 2004</xref>]; an exact penetrance figure is not known.</p>
        </sec>
        <sec id="ced.Anticipation">
          <title>Anticipation</title>
          <p>Earlier onset of symptoms and increased severity of symptoms and bone involvement in successive generations has been reported in several families [<xref ref-type="bibr" rid="ced.REF.wallace.2004.235">Wallace et al 2004</xref>, <xref ref-type="bibr" rid="ced.REF.janssens.2006.1">Janssens et al 2006</xref>]. If these findings represent anticipation rather than ascertainment bias (the latter being more likely), the mechanism of anticipation is unknown. Although multiple copies of the amino acid leucine can be encoded by one observed pathogenic variant in exon 1, the pathogenic variant was not found in these families.</p>
        </sec>
        <sec id="ced.Nomenclature">
          <title>Nomenclature</title>
          <p>Engelmann described the second reported occurrence of CED in 1929 as "osteopathic hyperostotica (sclerotisans) multiplex infantilis."</p>
          <p>The terms Engelmann disease and diaphyseal dysplasia were commonly used until <xref ref-type="bibr" rid="ced.REF.neuhauser.1948.11">Neuhauser et al [1948]</xref> coined the term progressive diaphyseal dysplasia.</p>
          <p><xref ref-type="bibr" rid="ced.REF.gulledge.1951.793">Gulledge &#x00026; White [1951]</xref> suggested the term progressive diaphyseal hyperostosis, which was not widely used.</p>
        </sec>
        <sec id="ced.Prevalence">
          <title>Prevalence</title>
          <p>The prevalence is unknown. More than 300 affected individuals have been reported. </p>
          <p>The disorder is pan ethnic.</p>
        </sec>
      </sec>
      <sec id="ced.Genetically_Related_Allelic_Disorder">
        <title>Genetically Related (Allelic) Disorders</title>
        <p>No phenotypes other than those discussed in this <italic toggle="yes">GeneReview</italic> are known to be associated with mutation of <italic toggle="yes">TGFB1.</italic>
</p>
      </sec>
      <sec id="ced.Differential_Diagnosis">
        <title>Differential Diagnosis</title>
        <p>Few disorders share the clinical and radiographic findings of Camurati-Engelmann disease (CED). The correct diagnosis is made by physical examination and skeletal survey.</p>
        <list list-type="bullet">
          <list-item>
            <p><bold>Craniodiaphyseal dysplasia</bold> (OMIM <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://omim.org/entry/218300">218300</ext-link>) is characterized by progressive and marked enlargement of the midline cranial bones causing a distinct facial deformity including nasal bridge widening and ocular hypertelorism. Cranial involvement in CED is milder and only on occasion results in frontal bossing and proptosis. The sclerosis of the long bones in craniodiaphyseal dysplasia is restricted to the diaphyses, which helps differentiate it from CED, in which the metaphyses can be affected as well. The gene(s) in which pathogenic variants occur have not been identified. Autosomal recessive inheritance is suggested. </p>
          </list-item>
          <list-item>
            <p><bold>Kenny-Caffey syndrome type 2</bold> (OMIM <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://omim.org/entry/127000">127000</ext-link>) is characterized by dwarfism, cortical thickening of the long bones, delayed fontanel closure, craniofacial anomalies, hypocalcemia, and hypoparathyroidism. Neither laboratory abnormalities nor delayed fontanel closure occurs in CED. Heterozygous <italic toggle="yes">FAM111A</italic> pathogenic variants are causative. Inheritance is autosomal dominant. </p>
          </list-item>
          <list-item>
            <p><bold>Juvenile Paget disease</bold> (OMIM <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://omim.org/entry/239000">239000</ext-link>) is characterized by a predisposition to fractures, coarse trabeculations, and bowing of the long bones. There is no predisposition to fractures or bowing of the long bones in CED. Biallelic <italic toggle="yes">TNFRSF11B</italic> pathogenic variants are causative. Inheritance is autosomal recessive. </p>
          </list-item>
          <list-item>
            <p><bold>Ghosal hematodiaphyseal dysplasia</bold> (OMIM <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://omim.org/entry/231095">231095</ext-link>) results in severe anemia and an increased susceptibility to infections. Diaphyseal dysplasia with anemia comprises endosteal bone formation with no evidence of subperiosteal bone formation. The presence of endosteal and subperiosteal bone deposition in CED helps distinguish it from the endosteal hyperostoses as well. Biallelic <italic toggle="yes">TBXAS1</italic> pathogenic variants are causative. Inheritance is autosomal recessive. </p>
          </list-item>
          <list-item>
            <p><bold>Endosteal hyperostosis, autosomal dominant</bold> (OMIM <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://omim.org/entry/144750">144750</ext-link>) is characterized by endosteal thickening without widening of the diaphyseal shaft. There is also a characteristic wide deep mandible with an increased gonial angle, which is distinct from the enlarged mandible found only occasionally in CED. Heterozygous <italic toggle="yes">LRP5</italic> pathogenic variants are causative. </p>
          </list-item>
          <list-item>
            <p><related-object link-type="booklink" source-id="gene" document-id="sost" document-type="chapter"><bold><italic toggle="yes">SOST</italic>-related sclerosing bone dysplasias</bold></related-object> include sclerosteosis (SCL) and van Buchem disease. A distinguishing clinical feature of SCL is variable syndactyly, usually of the second (index) and third (middle) fingers. The manifestations of van Buchem disease are generally milder than SCL, and syndactyly is absent. The <italic toggle="yes">SOST</italic>-related sclerosing bone dysplasias are inherited in an autosomal recessive manner, while CED is inherited in an autosomal dominant manner. Individuals with SCL and van Buchem disease have endosteal hyperostosis with smooth periosteal surfaces, whereas individuals with CED have periosteal thickening and an uneven, rough cortex. </p>
          </list-item>
        </list>
      </sec>
      <sec id="ced.Management">
        <title>Management</title>
        <sec id="ced.Evaluations_Following_Initial_Diagno">
          <title>Evaluations Following Initial Diagnosis</title>
          <p>To establish the extent of disease and needs in an individual diagnosed with Camurati-Engelmann disease (CED), the initial evaluation should include the following:</p>
          <list list-type="bullet">
            <list-item>
              <p>Complete skeletal survey (if not performed as part of the diagnostic work up)</p>
            </list-item>
            <list-item>
              <p>Assessment for cranial nerve deficits, including neurologic examination, hearing screen, and ophthalmologic evaluation</p>
            </list-item>
            <list-item>
              <p>Baseline blood pressure if considering treatment with losartan </p>
            </list-item>
            <list-item>
              <p>CBC to evaluate for anemia in individuals with significant endosteal involvement</p>
            </list-item>
            <list-item>
              <p>If acute bone pain is present, consideration of ESR and bone scan as baseline measures of disease activity</p>
            </list-item>
            <list-item>
              <p>In individuals with radiographic evidence of skull base sclerosis and neurologic symptoms, consideration of baseline CT of the head and neck to determine the extent of disease and allow consideration of surgical treatment options</p>
            </list-item>
            <list-item>
              <p>Medical genetics consultation</p>
            </list-item>
          </list>
        </sec>
        <sec id="ced.Treatment_of_Manifestations">
          <title>Treatment of Manifestations</title>
          <p>No consensus management guidelines have been developed to date.</p>
          <p><bold>Corticosteroids</bold> may relieve many of the symptoms of Camurati-Engelmann disease (CED). Several investigators report success with corticosteroid treatment in reducing pain and weakness; improving gait, exercise tolerance, and flexion contractures; and correcting anemia and hepatosplenomegaly [<xref ref-type="bibr" rid="ced.REF.lindstrom.1974.504">Lindstrom 1974</xref>, <xref ref-type="bibr" rid="ced.REF.ba_.1999.401">Ba&#x0015f; et al 1999</xref>, <xref ref-type="bibr" rid="ced.REF.wallace.2004.235">Wallace et al 2004</xref>]. Unsuccessful steroid therapy was reported in one adult. </p>
          <p>Individuals with severe symptoms can be treated with a bolus of prednisolone 1.0-2.0 mg/kg/day followed by rapid tapering to the lowest alternate-day dose tolerated. Less symptomatic individuals can be started on 0.5-1.0 mg/kg every other day. Some individuals may be able to discontinue steroid therapy during quiescent periods.</p>
          <p>Higher-dose steroids may help with acute pain crises.</p>
          <p>Note: Steroids may delay bone hyperostosis and prevent or delay the onset of skull involvement. Although histologic studies following steroid therapy showed increased bone resorption and secondary remodeling with increased osteoblastic activity and decreased lamellar bone deposition, several authors reported no regression of sclerosis on radiographic evaluation [<xref ref-type="bibr" rid="ced.REF.verbruggen.1985.809">Verbruggen et al 1985</xref>] or on scintigraphic evaluation [<xref ref-type="bibr" rid="ced.REF.ba_.1999.401">Ba&#x0015f; et al 1999</xref>]. <xref ref-type="bibr" rid="ced.REF.lindstrom.1974.504">Lindstrom [1974]</xref> and <xref ref-type="bibr" rid="ced.REF.ba_.1999.401">Ba&#x0015f; et al [1999]</xref> reported diminished sclerosis on radiographs following steroid therapy. <xref ref-type="bibr" rid="ced.REF.verbruggen.1985.809">Verbruggen et al [1985]</xref> and <xref ref-type="bibr" rid="ced.REF.inaoka.2001.680">Inaoka et al [2001]</xref> reported reduced radioactivity on bone scintigraphy. Long-term follow-up studies should be conducted to evaluate the success of corticosteroid therapy in preventing anemia, hepatosplenomegaly, headaches, and cranial nerve impingement. </p>
          <p><bold>Calcitonin.</bold> Pain relief from intranasal calcitonin is reported in one patient [<xref ref-type="bibr" rid="ced.REF.trombetti.2012.75">Trombetti et al 2012</xref>].</p>
          <p><bold>Losartan.</bold> Reduced bone pain and increased physical activity are reported in two patients treated with losartan [<xref ref-type="bibr" rid="ced.REF.ayyavoo.2014.3978">Ayyavoo et al 2014</xref>, <xref ref-type="bibr" rid="ced.REF.simsekkiper.2014.2667">Simsek-Kiper et al 2014</xref>]. Losartan has an anti-TGF&#x003b2; effect and is being tested in individuals with <related-object link-type="booklink" source-id="gene" document-id="marfan" document-type="chapter">Marfan syndrome</related-object>. </p>
          <p><bold>Other</bold> analgesics and non-pharmacologic methods are frequently used for alleviation of pain.</p>
          <p><bold>Surgical</bold> treatment for persistent bone pain by intramedullary reaming was reported in a woman age 22 years diagnosed with Ribbing disease [<xref ref-type="bibr" rid="ced.REF.ozt_rkmen.2011.58">Ozt&#x000fc;rkmen &#x00026; Karamehmeto&#x0011f;lu 2011</xref>]. Pain in the tibia resolved completely following the surgery; at five-year follow-up, the individual remained pain free. </p>
          <p>Craniectomy relieved increased intracranial pressure and headaches in two patients [Author, personal observation]. </p>
          <p><bold>Hearing loss</bold> evaluation by an otolaryngologist should include a BAER and a CT with fine cuts through the inner ear. Reports of successful treatment of hearing loss in CED are rare. Surgical decompression of the internal auditory canals can improve hearing. However, the skull hyperostosis is progressive, and cranial nerve compression often recurs.</p>
          <p>Corticosteroids may delay skull hyperostosis and cranial nerve impingement. <xref ref-type="bibr" rid="ced.REF.lindstrom.1974.504">Lindstrom [1974]</xref> reported no change in conductive hearing loss with steroid therapy. A woman age 30 years with a 75-dB neurosensory hearing loss on the right and a 65-dB neurosensory hearing loss of the left experienced some improvement in hearing with prednisone. Her hearing stabilized after decompression of the right internal auditory canal. </p>
          <p>Bilateral myringotomy can improve conductive hearing loss resulting from serous otitis in individuals with CED. </p>
          <p>A woman age 71 years with bilateral conductive hearing loss and patent internal auditory canals underwent a cochlear implantation, and speech detection improved from 75 dB to 45 dB [<xref ref-type="bibr" rid="ced.REF.friedland.2000.160">Friedland et al 2000</xref>]. General contraindications for cochlear implants include a narrowed internal auditory canal and absence of a functioning eighth nerve, both of which can be found in individuals with CED.</p>
          <p><xref ref-type="bibr" rid="ced.REF.carlson.2010.566">Carlson et al [2010]</xref> report six individuals with CED and bilateral sensorineural hearing loss. Three underwent internal auditory canal decompression with mixed results. Conservative management was used in the other three individuals with no worsening of symptoms (see also <related-object link-type="booklink" source-id="gene" document-id="deafness-overview" document-type="chapter">Hereditary Deafness and Hearing Loss Overview</related-object>).</p>
        </sec>
        <sec id="ced.Prevention_of_Primary_Manifestations">
          <title>Prevention of Primary Manifestations</title>
          <p>Initiation of steroids prior to the onset of proximal muscle weakness and/or sclerotic bone changes has not been reported. Because of the variable symptomatology and decreased penetrance, treatment of asymptomatic individuals cannot be recommended.</p>
          <p>
            <bold>Prevention of Secondary Complications</bold>
          </p>
          <p>Monitor blood pressure in individuals treated with corticosteroids and treat hypertension if necessary. </p>
          <p>Individuals taking losartan also need regular blood pressure monitoring due to the increased risk for hypotension.</p>
          <p>Taper corticosteroid dose as tolerated to reduce the risk of osteoporosis and compression fractures of the spine.</p>
        </sec>
        <sec id="ced.Surveillance">
          <title>Surveillance</title>
          <p>After initiating corticosteroids, affected individuals should be followed monthly, with efforts to taper the steroids to the lowest tolerated dose. Blood pressure should be monitored at each visit, as hypertension can develop following the initiation of steroid therapy.</p>
          <p>When a maintenance steroid dose is achieved, ongoing evaluations should include the following:</p>
          <list list-type="bullet">
            <list-item>
              <p>Annual: </p>
              <list list-type="bullet">
                <list-item>
                  <p>Complete neurologic examination</p>
                </list-item>
                <list-item>
                  <p>CBC</p>
                </list-item>
                <list-item>
                  <p>Measurement of blood pressure</p>
                </list-item>
                <list-item>
                  <p>Hearing screen</p>
                </list-item>
                <list-item>
                  <p>Evaluation of bone mineral densityNote: CED does not appear to cause an increase in spine density; therefore steroid therapy could lead to osteoporosis of the spine [Author, personal observation]. </p>
                </list-item>
              </list>
            </list-item>
            <list-item>
              <p>Routine monitoring of linear growth in children due to the possible side effect of delayed or stunted growth</p>
            </list-item>
          </list>
          <p>The authors are aware of one affected teenage individual who died of a dilated ascending aorta dissection. Whether this is related to CED is unknown. Because the mechanism of CED involves increased TGFB1 signaling, also found in <related-object link-type="booklink" source-id="gene" document-id="marfan" document-type="chapter">Marfan syndrome</related-object> and <related-object link-type="booklink" source-id="gene" document-id="loeys-dietz" document-type="chapter">Loeys-Dietz syndrome</related-object>, this death is of some concern. The authors are unaware of any other similar cases. Note: No recommendations for routine evaluation of the aorta can be made at this time.</p>
        </sec>
        <sec id="ced.AgentsCircumstances_to_Avoid">
          <title>Agents/Circumstances to Avoid </title>
          <p><bold>Bisphosphonates.</bold> Bone pain and uptake of 99mTc methylene diphosphonate by scintigraphy increased with pamidronate in a woman age 27 years with CED [<xref ref-type="bibr" rid="ced.REF.inaoka.2001.680">Inaoka et al 2001</xref>]. Clodronate infusion caused increased bone pain in one individual with CED and no improvement in another individual reported by <xref ref-type="bibr" rid="ced.REF.castro.2005.398">Castro et al [2005]</xref>. </p>
          <p><bold>Excess phosphate.</bold> Treatment with cellulose phosphate led to worsening hypocalcemia and proximal myopathy in another individual.</p>
        </sec>
        <sec id="ced.Evaluation_of_Relatives_at_Risk">
          <title>Evaluation of Relatives at Risk</title>
          <p>It is appropriate to evaluate relatives at risk in order to identify the diagnosis as early as possible, avoid potential misdiagnosis, and provide appropriate treatment for extremity pain. </p>
          <list list-type="bullet">
            <list-item>
              <p>If the <italic toggle="yes">TGFB1</italic> pathogenic variant in the family is known, molecular genetic testing can be used to clarify the genetic status of at-risk relatives.</p>
            </list-item>
            <list-item>
              <p>If the pathogenic variant in the family is not known, radiographic evaluation for hyperostosis can be used to clarify the disease status of at-risk relatives.</p>
            </list-item>
          </list>
          <p>See <xref ref-type="sec" rid="ced.Related_Genetic_Counseling_Issues">Genetic Counseling</xref> for issues related to testing of at-risk relatives for genetic counseling purposes.</p>
        </sec>
        <sec id="ced.Therapies_Under_Investigation">
          <title>Therapies Under Investigation</title>
          <p>Search <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://clinicaltrials.gov">ClinicalTrials.gov</ext-link> for access to information on clinical studies for a wide range of diseases and conditions. Note: There may not be clinical trials for this disorder.</p>
        </sec>
      </sec>
      <sec id="ced.Genetic_Counseling">
        <title>Genetic Counseling</title>
        <sec id="ced.Mode_of_Inheritance">
          <title>Mode of Inheritance</title>
          <p>Camurati-Engelmann disease (CED) is inherited in an autosomal dominant manner. </p>
        </sec>
        <sec id="ced.Risk_to_Family_Members">
          <title>Risk to Family Members</title>
          <p><bold>Parents of a proband</bold>
</p>
          <list list-type="bullet">
            <list-item>
              <p>Many individuals diagnosed with CED have an affected parent. </p>
            </list-item>
            <list-item>
              <p>A proband with CED may have the disorder as the result of <italic toggle="yes">de nov</italic>o mutation of <italic toggle="yes">TGFB1</italic>. The proportion of cases caused by <italic toggle="yes">de novo</italic> mutation is unknown. </p>
            </list-item>
            <list-item>
              <p>Recommendations for the evaluation of parents of a proband with an apparent <italic toggle="yes">de novo</italic> mutation include (a) molecular genetic testing if a <italic toggle="yes">TGFB1</italic> pathogenic variant has been identified in the proband or (b) a complete skeletal survey or AP radiographs of the extremities and a lateral skull film if the <italic toggle="yes">TGFB1</italic> pathogenic variant has not been identified in the proband. </p>
            </list-item>
            <list-item>
              <p>The family history of some individuals diagnosed with CED may appear to be negative because of failure to recognize the disorder in family members, early death of a parent before the onset of symptoms, or reduced penetrance in a parent. Therefore, an apparently negative family history cannot be confirmed unless appropriate evaluations (i.e., molecular genetic testing or radiographs) have been performed on the parents of the proband.</p>
            </list-item>
          </list>
          <p>Note: Though not reported, if the parent is the individual in whom the pathogenic variant first occurred, s/he may have somatic mosaicism for the variant and may be mildly/minimally affected.</p>
          <p><bold>Sibs of a proband</bold>
</p>
          <list list-type="bullet">
            <list-item>
              <p>The risk to the sibs of the proband depends on the genetic status of the proband's parents. </p>
            </list-item>
            <list-item>
              <p>If a parent of the proband is affected or has an identified pathogenic variant in <italic toggle="yes">TGFB1</italic>, the risk to the sibs of inheriting the pathogenic variant is 50%. </p>
            </list-item>
            <list-item>
              <p>Because of reduced penetrance, some individuals who inherit <italic toggle="yes">TGFB1</italic> pathogenic variants will not have manifestations. The exact penetrance is unknown. </p>
            </list-item>
            <list-item>
              <p>When the parents are clinically unaffected, molecular genetic testing can be used to identify individuals who have a <italic toggle="yes">TGFB1</italic> pathogenic variant but no clinical manifestations. The sibs of a proband with clinically unaffected parents are still at increased risk for CED because of the possibility of reduced penetrance in a parent.</p>
            </list-item>
            <list-item>
              <p>If the <italic toggle="yes">TGFB1</italic> pathogenic variant found in the proband cannot be detected in the DNA of either parent, the two possible genetic explanations are germline mosaicism in a parent or <italic toggle="yes">de novo</italic> mutation in the proband. Although no instances of germline mosaicism have been reported, it remains a possibility. </p>
            </list-item>
          </list>
          <p><bold>Offspring of a proband.</bold> Each child of an individual with CED has a 50% chance of inheriting the <italic toggle="yes">TGFB1</italic> pathogenic variant. </p>
          <p>
            <bold>Other family members of a proband</bold>
          </p>
          <list list-type="bullet">
            <list-item>
              <p>The risk to other family members depends on the genetic status of the proband's parents. </p>
            </list-item>
            <list-item>
              <p>If a parent is affected or has an identified pathogenic variant in <italic toggle="yes">TGFB1</italic>, his or her family members are at risk. </p>
            </list-item>
          </list>
        </sec>
        <sec id="ced.Related_Genetic_Counseling_Issues">
          <title>Related Genetic Counseling Issues</title>
          <p>See Management, <xref ref-type="sec" rid="ced.Evaluation_of_Relatives_at_Risk">Evaluation of Relatives at Risk</xref> for information on evaluating at-risk relatives for the purpose of early diagnosis and treatment.</p>
          <p><bold>Considerations in families with an apparent <italic toggle="yes">de novo</italic> mutation.</bold> When neither parent of a proband with CED has the <italic toggle="yes">TGFB1</italic> pathogenic variant or clinical evidence of the disorder, the <italic toggle="yes">TGFB1</italic> mutation is likely <italic toggle="yes">de novo</italic>. However, possible non-medical explanations including alternate paternity or maternity (e.g., with assisted reproduction) or undisclosed adoption could also be explored.</p>
          <p>
            <bold>Family planning</bold>
          </p>
          <list list-type="bullet">
            <list-item>
              <p>The optimal time for determination of genetic risk and discussion of the availability of prenatal testing is before pregnancy. </p>
            </list-item>
            <list-item>
              <p>It is appropriate to offer genetic counseling (including discussion of potential risks to offspring and reproductive options) to young adults who are affected or at risk.</p>
            </list-item>
          </list>
          <p><bold>DNA banking</bold> is the storage of DNA (typically extracted from white blood cells) for possible future use. Because it is likely that testing methodology and our understanding of genes, allelic variants, and diseases will improve in the future, consideration should be given to banking DNA of affected individuals. </p>
        </sec>
        <sec id="ced.Prenatal_Testing">
          <title>Prenatal Testing</title>
          <p>If the <italic toggle="yes">TGFB1</italic> pathogenic variant has been identified in an affected family member, prenatal testing for pregnancies at increased risk may be available from a clinical laboratory that offers either testing of this gene or custom prenatal testing. Because of reduced penetrance, results of prenatal testing may not be useful in accurately predicting age of onset, severity, type of symptoms, or rate of progression.</p>
          <p>Requests for prenatal testing for conditions which (like CED) do not affect intellect and have some treatment available are not common. Differences in perspective may exist among medical professionals and within families regarding the use of prenatal testing, particularly if the testing is being considered for the purpose of pregnancy termination rather than early diagnosis. Although most centers would consider decisions about prenatal testing to be the choice of the parents, discussion of these issues is appropriate.</p>
          <p><bold>Preimplantation genetic diagnosis (PGD)</bold> may be an option for some families in which the <italic toggle="yes">TGFB1</italic> pathogenic variant has been identified. </p>
        </sec>
      </sec>
      <sec id="ced.Resources">
        <title>Resources</title>
      </sec>
      <sec id="ced.Molecular_Genetics">
        <title>Molecular Genetics</title>
        <p><bold>Gene structure.</bold>
<italic toggle="yes">TGFB1</italic> has seven exons. For a detailed summary of gene and protein information, see <related-object source-id="gene" document-id="ced" object-id="ced.molgen.TA">Table A</related-object>, <bold>Gene</bold>.</p>
        <p><bold>Benign allelic variants.</bold> Several benign variants in <italic toggle="yes">TGFB1</italic> have been investigated for their effect on plasma TGFB1 levels and bone mineral density. These include a 5&#x02019;UTR in a consensus CREB halfsite [<xref ref-type="bibr" rid="ced.REF.grainger.1999.93">Grainger et al 1999</xref>], g.14128514A&#x0003e;G, c.29T&#x0003e;C in the signaling peptide resulting in a p.Leu10Pro amino acid substitution, c.-171delC, and an intron 5 variant [<xref ref-type="bibr" rid="ced.REF.keen.2001.48">Keen et al 2001</xref>]. Several other benign allelic variants have been identified [<xref ref-type="bibr" rid="ced.REF.ber_nek.2002.278">Ber&#x000e1;nek et al 2002</xref>] including c.74G&#x0003e;C in exon 1, resulting in a p.Arg25Pro substitution and c.788C&#x0003e;T in exon 5, resulting in a p.Thr263Ile substitution [<xref ref-type="bibr" rid="ced.REF.langdahl.1997.289">Langdahl et al 1997</xref>, <xref ref-type="bibr" rid="ced.REF.grainger.1999.93">Grainger et al 1999</xref>, <xref ref-type="bibr" rid="ced.REF.hinke.2001.315">Hinke et al 2001</xref>, <xref ref-type="bibr" rid="ced.REF.keen.2001.48">Keen et al 2001</xref>, <xref ref-type="bibr" rid="ced.REF.yamada.2001.149">Yamada et al 2001</xref>, <xref ref-type="bibr" rid="ced.REF.ziv.2003.227">Ziv et al 2003</xref>]. None of these benign allelic variants has been found to be associated with disease severity in families with Camurati-Engelmann disease (CED) [<xref ref-type="bibr" rid="ced.REF.camposxavier.2001.653">Campos-Xavier et al 2001</xref>, <xref ref-type="bibr" rid="ced.REF.wallace.2004.235">Wallace et al 2004</xref>]. </p>
        <p><xref ref-type="bibr" rid="ced.REF.watanabe.2002.478">Watanabe et al [2002]</xref> catalogued nine additional single-base substitution benign variants in introns. </p>
        <p><xref ref-type="bibr" rid="ced.REF.shah.2006.61">Shah et al [2006]</xref> identified a distal promoter segment and ten novel normal allelic variants. </p>
        <p><bold>Pathogenic allelic variants.</bold> Three pathogenic variants in exon 4 of <italic toggle="yes">TGFB1</italic> account for approximately 80% of the pathogenic variants observed in CED [<xref ref-type="bibr" rid="ced.REF.janssens.2000.273">Janssens et al 2000</xref>, <xref ref-type="bibr" rid="ced.REF.kinoshita.2000.19">Kinoshita et al 2000</xref>, <xref ref-type="bibr" rid="ced.REF.camposxavier.2001.653">Campos-Xavier et al 2001</xref>, <xref ref-type="bibr" rid="ced.REF.hecht.2001.198">Hecht et al 2001</xref>, <xref ref-type="bibr" rid="ced.REF.mumm.2001.593">Mumm et al 2001</xref>, <xref ref-type="bibr" rid="ced.REF.janssens.2003.7718">Janssens et al 2003</xref>, <xref ref-type="bibr" rid="ced.REF.kinoshita.2004.104">Kinoshita et al 2004</xref>, <xref ref-type="bibr" rid="ced.REF.wallace.2004.235">Wallace et al 2004</xref>, <xref ref-type="bibr" rid="ced.REF.janssens.2006.1">Janssens et al 2006</xref>]: </p>
        <list list-type="bullet">
          <list-item>
            <p>c.652C&#x0003e;T is found in about 40% of individuals. </p>
          </list-item>
          <list-item>
            <p>c.653G&#x0003e;A or c.673T&#x0003e;C is found in an additional 35% of individuals. </p>
          </list-item>
          <list-item>
            <p>Other selected pathogenic variants are listed in Table 2. </p>
          </list-item>
        </list>
        <p>For more information, see <related-object source-id="gene" document-id="ced" object-id="ced.molgen.TA">Table A</related-object>.</p>
        <table-wrap id="ced.T.selected_tgfb1_allelic_variants" position="anchor" orientation="portrait">
          <label>Table 2. </label>
          <caption>
            <p>Selected <italic toggle="yes">TGFB1</italic> Allelic Variants </p>
          </caption>
          <table frame="hsides" rules="groups">
            <thead>
              <tr>
                <th id="hd_h_ced.T.selected_tgfb1_allelic_variants_1_1_1_1" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Variant Classification</th>
                <th id="hd_h_ced.T.selected_tgfb1_allelic_variants_1_1_1_2" valign="middle" align="left" scope="col" rowspan="1" colspan="1">DNA Nucleotide Change<break/>(Alias&#x000a0;<sup>1</sup>)</th>
                <th id="hd_h_ced.T.selected_tgfb1_allelic_variants_1_1_1_3" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Protein Amino Acid Change </th>
                <th id="hd_h_ced.T.selected_tgfb1_allelic_variants_1_1_1_4" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Reference Sequences</th>
              </tr>
            </thead>
            <tbody>
              <tr>
                <td headers="hd_h_ced.T.selected_tgfb1_allelic_variants_1_1_1_1" rowspan="5" valign="middle" align="left" scope="row" colspan="1">
                  <bold>Benign</bold>
                </td>
                <td headers="hd_h_ced.T.selected_tgfb1_allelic_variants_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">g.14128514A&#x0003e;G<break/>(-1347C&#x0003e;T)</td>
                <td headers="hd_h_ced.T.selected_tgfb1_allelic_variants_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">--</td>
                <td headers="hd_h_ced.T.selected_tgfb1_allelic_variants_1_1_1_4" valign="middle" align="left" rowspan="1" colspan="1">
                  <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/nuccore/29800594">NT_011109.15</ext-link>
                  <break/>
                  <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/projects/SNP/snp_ref.cgi?rs=1800469">rs1800469</ext-link>
                </td>
              </tr>
              <tr>
                <td headers="hd_h_ced.T.selected_tgfb1_allelic_variants_1_1_1_2" valign="middle" colspan="1" align="left" scope="row" rowspan="1">c.29C&#x0003e;T</td>
                <td headers="hd_h_ced.T.selected_tgfb1_allelic_variants_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">p.Leu10Pro</td>
                <td headers="hd_h_ced.T.selected_tgfb1_allelic_variants_1_1_1_4" rowspan="4" valign="middle" align="left" colspan="1">
                  <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/nuccore/260655621">NM_000660.4</ext-link>
                  <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/protein/63025222">NP_000651.3</ext-link>
                </td>
              </tr>
              <tr>
                <td headers="hd_h_ced.T.selected_tgfb1_allelic_variants_1_1_1_2" valign="middle" colspan="1" align="left" scope="row" rowspan="1">c.-171delC<break/>(11007delC)</td>
                <td headers="hd_h_ced.T.selected_tgfb1_allelic_variants_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">--</td>
              </tr>
              <tr>
                <td headers="hd_h_ced.T.selected_tgfb1_allelic_variants_1_1_1_2" valign="middle" colspan="1" align="left" scope="row" rowspan="1">c.74G&#x0003e;C<break/>(75G&#x0003e;C)</td>
                <td headers="hd_h_ced.T.selected_tgfb1_allelic_variants_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">p.Arg25Pro</td>
              </tr>
              <tr>
                <td headers="hd_h_ced.T.selected_tgfb1_allelic_variants_1_1_1_2" valign="middle" colspan="1" align="left" scope="row" rowspan="1">c.788C&#x0003e;T<break/>(11935C&#x0003e;T)</td>
                <td headers="hd_h_ced.T.selected_tgfb1_allelic_variants_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">p.Thr263Ile</td>
              </tr>
              <tr>
                <td headers="hd_h_ced.T.selected_tgfb1_allelic_variants_1_1_1_1" rowspan="11" valign="middle" align="left" scope="row" colspan="1">
                  <bold>Pathogenic</bold>
                </td>
                <td headers="hd_h_ced.T.selected_tgfb1_allelic_variants_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">c.30_38dup</td>
                <td headers="hd_h_ced.T.selected_tgfb1_allelic_variants_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">p.Leu11_Leu13dup</td>
                <td headers="hd_h_ced.T.selected_tgfb1_allelic_variants_1_1_1_4" rowspan="11" valign="middle" align="left" colspan="1">
                  <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/nuccore/NM_000660?log$=seqview_status">NM_000660.4</ext-link>
                  <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/protein/63025222">NP_000651.3</ext-link>
                </td>
              </tr>
              <tr>
                <td headers="hd_h_ced.T.selected_tgfb1_allelic_variants_1_1_1_2" valign="middle" colspan="1" align="left" scope="row" rowspan="1">c.241T&#x0003e;C</td>
                <td headers="hd_h_ced.T.selected_tgfb1_allelic_variants_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">p.Tyr81His</td>
              </tr>
              <tr>
                <td headers="hd_h_ced.T.selected_tgfb1_allelic_variants_1_1_1_2" valign="middle" colspan="1" align="left" scope="row" rowspan="1">c.466C&#x0003e;T</td>
                <td headers="hd_h_ced.T.selected_tgfb1_allelic_variants_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">p.Arg156Cys</td>
              </tr>
              <tr>
                <td headers="hd_h_ced.T.selected_tgfb1_allelic_variants_1_1_1_2" valign="middle" colspan="1" align="left" scope="row" rowspan="1">c.505G&#x0003e;A</td>
                <td headers="hd_h_ced.T.selected_tgfb1_allelic_variants_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">p.Glu169Lys</td>
              </tr>
              <tr>
                <td headers="hd_h_ced.T.selected_tgfb1_allelic_variants_1_1_1_2" valign="middle" colspan="1" align="left" scope="row" rowspan="1">c.652C&#x0003e;T</td>
                <td headers="hd_h_ced.T.selected_tgfb1_allelic_variants_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">p.Arg218Cys</td>
              </tr>
              <tr>
                <td headers="hd_h_ced.T.selected_tgfb1_allelic_variants_1_1_1_2" valign="middle" colspan="1" align="left" scope="row" rowspan="1">c.653G&#x0003e;A</td>
                <td headers="hd_h_ced.T.selected_tgfb1_allelic_variants_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">p.Arg218His</td>
              </tr>
              <tr>
                <td headers="hd_h_ced.T.selected_tgfb1_allelic_variants_1_1_1_2" valign="middle" colspan="1" align="left" scope="row" rowspan="1">c.664C&#x0003e;G</td>
                <td headers="hd_h_ced.T.selected_tgfb1_allelic_variants_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">p.His222Asp</td>
              </tr>
              <tr>
                <td headers="hd_h_ced.T.selected_tgfb1_allelic_variants_1_1_1_2" valign="middle" colspan="1" align="left" scope="row" rowspan="1">c.667T&#x0003e;A</td>
                <td headers="hd_h_ced.T.selected_tgfb1_allelic_variants_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">p.Cys223Ser</td>
              </tr>
              <tr>
                <td headers="hd_h_ced.T.selected_tgfb1_allelic_variants_1_1_1_2" valign="middle" colspan="1" align="left" scope="row" rowspan="1">c.667T&#x0003e;C</td>
                <td headers="hd_h_ced.T.selected_tgfb1_allelic_variants_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">p.Cys223Arg</td>
              </tr>
              <tr>
                <td headers="hd_h_ced.T.selected_tgfb1_allelic_variants_1_1_1_2" valign="middle" colspan="1" align="left" scope="row" rowspan="1">c.667T&#x0003e;G</td>
                <td headers="hd_h_ced.T.selected_tgfb1_allelic_variants_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">p.Cys223Gly</td>
              </tr>
              <tr>
                <td headers="hd_h_ced.T.selected_tgfb1_allelic_variants_1_1_1_2" valign="middle" colspan="1" align="left" scope="row" rowspan="1">c.673T&#x0003e;C</td>
                <td headers="hd_h_ced.T.selected_tgfb1_allelic_variants_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">p.Cys225Arg</td>
              </tr>
            </tbody>
          </table>
          <table-wrap-foot>
            <fn>
              <p>Note on variant classification: Variants listed in the table have been provided by the authors. <italic toggle="yes">GeneReviews</italic> staff have not independently verified the classification of variants. </p>
            </fn>
            <fn>
              <p>Note on nomenclature: <italic toggle="yes">GeneReviews</italic> follows the standard naming conventions of the Human Genome Variation Society (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://varnomen.hgvs.org/">varnomen.hgvs.org</ext-link>). See <related-object link-type="booklink" source-id="gene" document-id="app3" document-type="appendix">Quick Reference</related-object> for an explanation of nomenclature. </p>
            </fn>
            <fn id="ced.TF.2.1">
              <label>1. </label>
              <p>Variant designation that does not conform to current naming conventions</p>
            </fn>
          </table-wrap-foot>
        </table-wrap>
        <p><bold>Normal gene product.</bold> Transforming growth factor beta-1 (TGF-&#x003b2;1) is synthesized as a large precursor molecule. TGF-&#x003b2;1 preprotein contains a signal peptide of 29 amino acids that is proteolytically cleaved. TGF-&#x003b2;1 is further cleaved after amino acid 278 to form latency-associated peptide (LAP) and active TGF-&#x003b2;1. LAP dimerizes with interchain disulfide links at Cys223 and Cys225. TGF-&#x003b2;1 can be secreted as an inactive small latent complex that consists of a mature TGF-&#x003b2;1 homodimer non-covalently associated with an LAP homodimer at LAP residues Ile<sup>53</sup>-Leu<sup>59</sup>. LAP shields the type II receptor binding sites in the mature TGF-&#x003b2;1. Most cells secrete TGF-&#x003b2;1 as a large latent complex (LLC) of TGF-&#x003b2;1/LAP covalently bound between Cys<sup>33</sup> in the LAP chains and latent TGFB-binding protein (LTBP). LTBPs facilitate TGF-&#x003b2;1 folding, secretion, and possibly targeting to the extracellular matrix. Activation of the LLC occurs via the N-terminal domain of LTBP binding to the extracellular matrix.</p>
        <p><bold>Abnormal gene product.</bold> The majority of pathogenic variants in individuals with CED result in single amino-acid substitutions in the carboxy terminus of TGF-&#x003b2;1 latency-associated peptide (LAP). The substitutions are near the site of interchain disulfide bonds between the LAP homodimers. These pathogenic variants disrupt dimerization of LAP and binding to active TGF-&#x003b2;1 [<xref ref-type="bibr" rid="ced.REF.walton.2010.17029">Walton et al 2010</xref>], leading to increased active TGF-&#x003b2;1 release from the cell. p.Arg218His mutant fibroblasts from individuals with CED showed increased active TGF-&#x003b2;1 in the cell media compared to normal fibroblasts [<xref ref-type="bibr" rid="ced.REF.saito.2001.11469">Saito &#x00026; Kinoshita 2001</xref>]. In vitro analysis of p.Arg218Cys, p.His222Asp, and p.Cys225Arg mutant constructs also showed increased active TGF-&#x003b2;1 in the medium of transfected cells. In contrast, the p.Leu11_Leu13dup and p.Tyr81His pathogenic variants caused a decrease in the amount of TGF-&#x003b2;1 secreted. However, in a luciferase reporter assay specific for TGF-&#x003b2;1-induced transcriptional response, the mutant cells showed increased luciferase activity, suggesting intracellular activation of the receptor [<xref ref-type="bibr" rid="ced.REF.janssens.2003.7718">Janssens et al 2003</xref>]. </p>
      </sec>
      <sec id="ced.References">
        <title>References</title>
        <sec id="ced.Literature_Cited">
          <title>Literature Cited </title>
          <ref-list id="ced.Literature_Cited.reflist0">
            <ref id="ced.REF.ayyavoo.2014.3978">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Ayyavoo</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Derraik</surname>
                    <given-names>JGB</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cutfield</surname>
                    <given-names>WS</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hofman</surname>
                    <given-names>PL</given-names>
                  </name>
                </person-group>
                <year>2014</year>
                <article-title>Elimination of pain and improvement of exercise capacity in Camurati-Engelmann disease with losartan.</article-title>
                <source>J Clin Endocrinol Metab</source>
                <volume>99</volume>
                <fpage>3978</fpage>
                <lpage>82</lpage>
                <pub-id pub-id-type="pmid">25140400</pub-id>
              </element-citation>
            </ref>
            <ref id="ced.REF.ba_.1999.401">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Ba&#x0015f;</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Darendeliler</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Petorak</surname>
                    <given-names>I</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sadikoglu</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bilir</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bundak</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Saka</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gunoz</surname>
                    <given-names>H</given-names>
                  </name>
                </person-group>
                <year>1999</year>
                <article-title>Deflazacort treatment in progressive diaphyseal dysplasia (Camurati-Engelmann disease).</article-title>
                <source>J Paediatr Child Health</source>
                <volume>35</volume>
                <fpage>401</fpage>
                <lpage>5</lpage>
                <pub-id pub-id-type="pmid">10457303</pub-id>
              </element-citation>
            </ref>
            <ref id="ced.REF.ber_nek.2002.278">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Ber&#x000e1;nek</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kankov&#x000e1;</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Benes</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Izakovicov&#x000e1;-Holl&#x000e1;</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Znojil</surname>
                    <given-names>V</given-names>
                  </name>
                  <name name-style="western">
                    <surname>H&#x000e1;jek</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Vlkov&#x000e1;</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>V&#x000e1;cha</surname>
                    <given-names>J</given-names>
                  </name>
                </person-group>
                <year>2002</year>
                <article-title>Polymorphism R25P in the gene encoding transforming growth factor-beta (TGF-beta1) is a newly identified risk factor for proliferative diabetic retinopathy.</article-title>
                <source>Am J Med Genet.</source>
                <volume>109</volume>
                <fpage>278</fpage>
                <lpage>83</lpage>
                <pub-id pub-id-type="pmid">11992481</pub-id>
              </element-citation>
            </ref>
            <ref id="ced.REF.camposxavier.2001.653">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Campos-Xavier</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Saraiva</surname>
                    <given-names>JM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Savarirayan</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Verloes</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Feingold</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Faivre</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Munnich</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Le Merrer</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cormier-Daire</surname>
                    <given-names>V</given-names>
                  </name>
                </person-group>
                <year>2001</year>
                <article-title>Phenotypic variability at the TGF-beta1 locus in Camurati-Engelmann disease.</article-title>
                <source>Hum Genet</source>
                <volume>109</volume>
                <fpage>653</fpage>
                <lpage>8</lpage>
                <pub-id pub-id-type="pmid">11810278</pub-id>
              </element-citation>
            </ref>
            <ref id="ced.REF.carlson.2010.566">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Carlson</surname>
                    <given-names>ML</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Beatty</surname>
                    <given-names>CW</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Neff</surname>
                    <given-names>BA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Link</surname>
                    <given-names>MJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Driscoll</surname>
                    <given-names>CL</given-names>
                  </name>
                </person-group>
                <year>2010</year>
                <article-title>Skull base manifestations of Camurati-Engelmann disease.</article-title>
                <source>Arch Otolaryngol Head Neck Surg</source>
                <volume>136</volume>
                <fpage>566</fpage>
                <lpage>75</lpage>
                <pub-id pub-id-type="pmid">20566907</pub-id>
              </element-citation>
            </ref>
            <ref id="ced.REF.castro.2005.398">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Castro</surname>
                    <given-names>GR</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Appenzeller</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Marques-Neto</surname>
                    <given-names>JF</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bertolo</surname>
                    <given-names>MB</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Samara</surname>
                    <given-names>AM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Coimbra</surname>
                    <given-names>I</given-names>
                  </name>
                </person-group>
                <year>2005</year>
                <article-title>Camurati-Engelmann disease: failure of response to bisphosphonates: report of two cases.</article-title>
                <source>Clin Rheumatol</source>
                <volume>24</volume>
                <fpage>398</fpage>
                <lpage>401</lpage>
                <pub-id pub-id-type="pmid">15660289</pub-id>
              </element-citation>
            </ref>
            <ref id="ced.REF.friedland.2000.160">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Friedland</surname>
                    <given-names>DR</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wackym</surname>
                    <given-names>PA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rhee</surname>
                    <given-names>JS</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Finn</surname>
                    <given-names>MS</given-names>
                  </name>
                </person-group>
                <year>2000</year>
                <article-title>Cochlear implantation for auditory rehabilitation in Camurati-Engelmann disease.</article-title>
                <source>Ann Otol Rhinol Laryngol</source>
                <volume>109</volume>
                <fpage>160</fpage>
                <lpage>2</lpage>
                <pub-id pub-id-type="pmid">10685567</pub-id>
              </element-citation>
            </ref>
            <ref id="ced.REF.grainger.1999.93">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Grainger</surname>
                    <given-names>DJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Heathcote</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Chiano</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Snieder</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kemp</surname>
                    <given-names>PR</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Metcalfe</surname>
                    <given-names>JC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Carter</surname>
                    <given-names>ND</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Spector</surname>
                    <given-names>TD</given-names>
                  </name>
                </person-group>
                <year>1999</year>
                <article-title>Genetic control of the circulating concentration of transforming growth factor type beta1.</article-title>
                <source>Hum Mol Genet</source>
                <volume>8</volume>
                <fpage>93</fpage>
                <lpage>7</lpage>
                <pub-id pub-id-type="pmid">9887336</pub-id>
              </element-citation>
            </ref>
            <ref id="ced.REF.gulledge.1951.793">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Gulledge</surname>
                    <given-names>WH</given-names>
                  </name>
                  <name name-style="western">
                    <surname>White</surname>
                    <given-names>JW</given-names>
                  </name>
                </person-group>
                <year>1951</year>
                <article-title>Englemann's disease (progressive diaphyseal hyperostosis); report of a case.</article-title>
                <source>J Bone Joint Surg Am</source>
                <volume>33-A</volume>
                <fpage>793</fpage>
                <lpage>7</lpage>
                <pub-id pub-id-type="pmid">14850520</pub-id>
              </element-citation>
            </ref>
            <ref id="ced.REF.gupta.2005.399">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Gupta</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cheikh</surname>
                    <given-names>IE</given-names>
                  </name>
                </person-group>
                <year>2005</year>
                <article-title>Camurati-Engelmann disease in conjunction with hypogonadism.</article-title>
                <source>Endocr Pract</source>
                <volume>11</volume>
                <fpage>399</fpage>
                <lpage>407</lpage>
                <pub-id pub-id-type="pmid">16638728</pub-id>
              </element-citation>
            </ref>
            <ref id="ced.REF.hecht.2001.198">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Hecht</surname>
                    <given-names>JT</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Blanton</surname>
                    <given-names>SH</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Broussard</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Scott</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rhoades Hall</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Milunsky</surname>
                    <given-names>JM</given-names>
                  </name>
                </person-group>
                <year>2001</year>
                <article-title>Evidence for locus heterogeneity in the Camurati-Engelmann (DPD1) Syndrome.</article-title>
                <source>Clin Genet</source>
                <volume>59</volume>
                <fpage>198</fpage>
                <lpage>200</lpage>
                <pub-id pub-id-type="pmid">11260231</pub-id>
              </element-citation>
            </ref>
            <ref id="ced.REF.hinke.2001.315">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Hinke</surname>
                    <given-names>V</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Seck</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Clanget</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Scheidt-Nave</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ziegler</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pfeilschifter</surname>
                    <given-names>J</given-names>
                  </name>
                </person-group>
                <year>2001</year>
                <article-title>Association of transforming growth factor-beta1 (TGFbeta1) T29 --&#x0003e; C gene polymorphism with bone mineral density (BMD), changes in BMD, and serum concentrations of TGF-beta1 in a population-based sample of postmenopausal german women.</article-title>
                <source>Calcif Tissue Int</source>
                <volume>69</volume>
                <fpage>315</fpage>
                <lpage>20</lpage>
                <pub-id pub-id-type="pmid">11800227</pub-id>
              </element-citation>
            </ref>
            <ref id="ced.REF.inaoka.2001.680">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Inaoka</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Shuke</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sato</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ishikawa</surname>
                    <given-names>Y</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Takahashi</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Aburano</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Makita</surname>
                    <given-names>Y</given-names>
                  </name>
                </person-group>
                <year>2001</year>
                <article-title>Scintigraphic evaluation of pamidronate and corticosteroid therapy in a patient with progressive diaphyseal dysplasia (Camurati-Engelmann disease).</article-title>
                <source>Clin Nucl Med</source>
                <volume>26</volume>
                <fpage>680</fpage>
                <lpage>2</lpage>
                <pub-id pub-id-type="pmid">11452173</pub-id>
              </element-citation>
            </ref>
            <ref id="ced.REF.janssens.2000.273">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Janssens</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gershoni-Baruch</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Guanabens</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Migone</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ralston</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bonduelle</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lissens</surname>
                    <given-names>W</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Van Maldergem</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Vanhoenacker</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Verbruggen</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Van Hul</surname>
                    <given-names>W</given-names>
                  </name>
                </person-group>
                <year>2000</year>
                <article-title>Mutations in the gene encoding the latency-associated peptide of TGF-beta 1 cause Camurati-Engelmann disease.</article-title>
                <source>Nat Genet</source>
                <volume>26</volume>
                <fpage>273</fpage>
                <lpage>5</lpage>
                <pub-id pub-id-type="pmid">11062463</pub-id>
              </element-citation>
            </ref>
            <ref id="ced.REF.janssens.2003.7718">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Janssens</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>ten Dijke</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ralston</surname>
                    <given-names>SH</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bergmann</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Van Hul</surname>
                    <given-names>W</given-names>
                  </name>
                </person-group>
                <year>2003</year>
                <article-title>Transforming growth factor-beta 1 mutations in Camurati-Engelmann disease lead to increased signaling by altering either activation or secretion of the mutant protein.</article-title>
                <source>J Biol Chem</source>
                <volume>278</volume>
                <fpage>7718</fpage>
                <lpage>24</lpage>
                <pub-id pub-id-type="pmid">12493741</pub-id>
              </element-citation>
            </ref>
            <ref id="ced.REF.janssens.2006.1">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Janssens</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Vanhoenacker</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bonduelle</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Verbruggen</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Van Maldergem</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ralston</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Guanabens</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Migone</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wientroub</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Divizia</surname>
                    <given-names>MT</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bergmann</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bennett</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Simsek</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Melancon</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cundy</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Van Hul</surname>
                    <given-names>W</given-names>
                  </name>
                </person-group>
                <year>2006</year>
                <article-title>Camurati-Engelmann disease: review of the clinical, radiological, and molecular data of 24 families and implications for diagnosis and treatment.</article-title>
                <source>J Med Genet</source>
                <volume>43</volume>
                <fpage>1</fpage>
                <lpage>11</lpage>
                <pub-id pub-id-type="pmid">15894597</pub-id>
              </element-citation>
            </ref>
            <ref id="ced.REF.keen.2001.48">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Keen</surname>
                    <given-names>RW</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Snieder</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Molloy</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Daniels</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Chiano</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gibson</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Fairbairn</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Smith</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>MacGregor</surname>
                    <given-names>AJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gewert</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Spector</surname>
                    <given-names>TD</given-names>
                  </name>
                </person-group>
                <year>2001</year>
                <article-title>Evidence of association and linkage disequilibrium between a novel polymorphism in the transforming growth factor beta 1 gene and hip bone mineral density: a study of female twins.</article-title>
                <source>Rheumatology (Oxford)</source>
                <volume>40</volume>
                <fpage>48</fpage>
                <lpage>54</lpage>
                <pub-id pub-id-type="pmid">11157141</pub-id>
              </element-citation>
            </ref>
            <ref id="ced.REF.kinoshita.2004.104">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Kinoshita</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Fukumaki</surname>
                    <given-names>Y</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Shirahama</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Miyahara</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Nishimura</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Haga</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Namba</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ueda</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hayashi</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ikegawa</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Seidel</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Niikawa</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Yoshiura</surname>
                    <given-names>K</given-names>
                  </name>
                </person-group>
                <year>2004</year>
                <article-title>TGFB1 mutations in four new families with Camurati-Engelmann disease: Confirmation of independently arising LAP-domain-specific mutations.</article-title>
                <source>Am J Med Genet</source>
                <volume>127A</volume>
                <fpage>104</fpage>
                <lpage>7</lpage>
                <pub-id pub-id-type="pmid">15103729</pub-id>
              </element-citation>
            </ref>
            <ref id="ced.REF.kinoshita.2000.19">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Kinoshita</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Saito</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tomita</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Makita</surname>
                    <given-names>Y</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Yoshida</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ghadami</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Yamada</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kondo</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ikegawa</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Nishimura</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Fukushima</surname>
                    <given-names>Y</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Nakagomi</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Saito</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sugimoto</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kamegaya</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hisa</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Murray</surname>
                    <given-names>JC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Taniguchi</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Niikawa</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Yoshiura</surname>
                    <given-names>K</given-names>
                  </name>
                </person-group>
                <year>2000</year>
                <article-title>Domain-specific mutations in TGFB1 result in Camurati-Engelmann disease.</article-title>
                <source>Nat Genet</source>
                <volume>26</volume>
                <fpage>19</fpage>
                <lpage>20</lpage>
                <pub-id pub-id-type="pmid">10973241</pub-id>
              </element-citation>
            </ref>
            <ref id="ced.REF.langdahl.1997.289">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Langdahl</surname>
                    <given-names>BL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Knudsen</surname>
                    <given-names>JY</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Jensen</surname>
                    <given-names>HK</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gregersen</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Eriksen</surname>
                    <given-names>EF</given-names>
                  </name>
                </person-group>
                <year>1997</year>
                <article-title>A sequence variation: 713-8delC in the transforming growth factor-beta 1 gene has higher prevalence in osteoporotic women than in normal women and is associated with very low bone mass in osteoporotic women and increased bone turnover in both osteoporotic and normal women.</article-title>
                <source>Bone</source>
                <volume>20</volume>
                <fpage>289</fpage>
                <lpage>94</lpage>
                <pub-id pub-id-type="pmid">9071481</pub-id>
              </element-citation>
            </ref>
            <ref id="ced.REF.lindstrom.1974.504">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Lindstrom</surname>
                    <given-names>JA</given-names>
                  </name>
                </person-group>
                <year>1974</year>
                <article-title>Diaphyseal dysplasia (Engelmann) treated with corticosteroids.</article-title>
                <source>Birth Defects Orig Artic Ser</source>
                <volume>10</volume>
                <fpage>504</fpage>
                <lpage>7</lpage>
                <pub-id pub-id-type="pmid">4461085</pub-id>
              </element-citation>
            </ref>
            <ref id="ced.REF.makita.2000.153">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Makita</surname>
                    <given-names>Y</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Nishimura</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ikegawa</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ishii</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ito</surname>
                    <given-names>Y</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Okuno</surname>
                    <given-names>A</given-names>
                  </name>
                </person-group>
                <year>2000</year>
                <article-title>Intrafamilial phenotypic variability in Engelmann disease (ED): are ED and Ribbing disease the same entity?</article-title>
                <source>Am J Med Genet</source>
                <volume>91</volume>
                <fpage>153</fpage>
                <lpage>6</lpage>
                <pub-id pub-id-type="pmid">10748417</pub-id>
              </element-citation>
            </ref>
            <ref id="ced.REF.mumm.2001.593">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Mumm</surname>
                    <given-names>SR</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Obrecht</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Podgornik</surname>
                    <given-names>MN</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Whyte</surname>
                    <given-names>MP</given-names>
                  </name>
                </person-group>
                <year>2001</year>
                <article-title>Camurati-Engelmann disease: New mutations in the latency-associated peptide of the transforming growth factor B-1 gene.</article-title>
                <source>Am J Hum Genet</source>
                <volume>69S</volume>
                <fpage>593</fpage>
              </element-citation>
            </ref>
            <ref id="ced.REF.neuhauser.1948.11">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Neuhauser</surname>
                    <given-names>EBD</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Schwachman</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wittenborg</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cohen</surname>
                    <given-names>J</given-names>
                  </name>
                </person-group>
                <year>1948</year>
                <article-title>Progressive diaphyseal dysplasia.</article-title>
                <source>Radiology</source>
                <volume>51</volume>
                <fpage>11</fpage>
                <lpage>22</lpage>
                <pub-id pub-id-type="pmid">18869144</pub-id>
              </element-citation>
            </ref>
            <ref id="ced.REF.ozt_rkmen.2011.58">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Ozt&#x000fc;rkmen</surname>
                    <given-names>Y</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Karamehmeto&#x0011f;lu</surname>
                    <given-names>M</given-names>
                  </name>
                </person-group>
                <year>2011</year>
                <article-title>Ribbing disease: a case report and literature review.</article-title>
                <source>Acta Orthop Traumatol Turc</source>
                <volume>45</volume>
                <fpage>58</fpage>
                <lpage>65</lpage>
                <pub-id pub-id-type="pmid">21478664</pub-id>
              </element-citation>
            </ref>
            <ref id="ced.REF.saito.2001.11469">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Saito</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kinoshita</surname>
                    <given-names>A</given-names>
                  </name>
                </person-group>
                <article-title>Yoshiura Ki, Makita Y, Wakui K, Honke K, Niikawa N, Taniguchi N. Domain-specific mutations of a transforming growth factor (TGF)-beta 1 latency-associated peptide cause Camurati-Engelmann disease because of the formation of a constitutively active form of TGF-beta 1.</article-title>
                <source>J Biol Chem.</source>
                <year>2001</year>
                <volume>276</volume>
                <fpage>11469</fpage>
                <lpage>72</lpage>
                <pub-id pub-id-type="pmid">11278244</pub-id>
              </element-citation>
            </ref>
            <ref id="ced.REF.shah.2006.61">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Shah</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rahaman</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hurley</surname>
                    <given-names>CK</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Posch</surname>
                    <given-names>PE</given-names>
                  </name>
                </person-group>
                <year>2006</year>
                <article-title>Allelic diversity in the TGFB1 regulatory region: characterization of novel functional single nucleotide polymorphisms.</article-title>
                <source>Hum Genet</source>
                <volume>119</volume>
                <fpage>61</fpage>
                <lpage>74</lpage>
                <pub-id pub-id-type="pmid">16369764</pub-id>
              </element-citation>
            </ref>
            <ref id="ced.REF.simsekkiper.2014.2667">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Simsek-Kiper</surname>
                    <given-names>PO</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Dikoglu</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Campos-Xavier</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Utine</surname>
                    <given-names>GE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bonafe</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Unger</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Boduroglu</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Superti-Furga</surname>
                    <given-names>A</given-names>
                  </name>
                </person-group>
                <article-title>Positive effects of an angiotensin II type 1 receptor antagonist in Camurati-Engelmann disease: a single case observation.</article-title>
                <source>Am J Med Genet A.</source>
                <year>2014</year>
                <volume>164A</volume>
                <fpage>2667</fpage>
                <lpage>71</lpage>
                <pub-id pub-id-type="pmid">25099136</pub-id>
              </element-citation>
            </ref>
            <ref id="ced.REF.trombetti.2012.75">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Trombetti</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cortes</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kaelin</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Morris</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rizzoli</surname>
                    <given-names>R</given-names>
                  </name>
                </person-group>
                <year>2012</year>
                <article-title>Intranasal calcitonin reducing bone pain in a patient with Camurati-Engelmann disease.</article-title>
                <source>Scand J Rheumatol</source>
                <volume>41</volume>
                <fpage>75</fpage>
                <lpage>7</lpage>
                <pub-id pub-id-type="pmid">22044122</pub-id>
              </element-citation>
            </ref>
            <ref id="ced.REF.verbruggen.1985.809">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Verbruggen</surname>
                    <given-names>LA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bossuyt</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Schreuer</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Somers</surname>
                    <given-names>G</given-names>
                  </name>
                </person-group>
                <year>1985</year>
                <article-title>Clinical and scintigraphic evaluation of corticosteroid treatment in a case of progressive diaphyseal dysplasia.</article-title>
                <source>J Rheumatol</source>
                <volume>12</volume>
                <fpage>809</fpage>
                <lpage>13</lpage>
                <pub-id pub-id-type="pmid">4057207</pub-id>
              </element-citation>
            </ref>
            <ref id="ced.REF.wallace.2004.235">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Wallace</surname>
                    <given-names>SE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lachman</surname>
                    <given-names>RS</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mekikian</surname>
                    <given-names>PB</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bui</surname>
                    <given-names>KK</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wilcox</surname>
                    <given-names>WR</given-names>
                  </name>
                </person-group>
                <year>2004</year>
                <article-title>Marked phenotypic variability in progressive diaphyseal dysplasia (Camurati-Engelmann disease): report of a four-generation pedigree, identification of a mutation in TGFB1, and review.</article-title>
                <source>Am J Med Genet</source>
                <volume>129A</volume>
                <fpage>235</fpage>
                <lpage>47</lpage>
                <pub-id pub-id-type="pmid">15326622</pub-id>
              </element-citation>
            </ref>
            <ref id="ced.REF.walton.2010.17029">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Walton</surname>
                    <given-names>KL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Makanji</surname>
                    <given-names>Y</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Chen</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wilce</surname>
                    <given-names>MC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Chan</surname>
                    <given-names>KL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Robertson</surname>
                    <given-names>DM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Harrison</surname>
                    <given-names>CA</given-names>
                  </name>
                </person-group>
                <year>2010</year>
                <article-title>Two distinct regions of latency-associated peptide coordinate stability of the latent transforming growth factor-<italic toggle="yes">&#x003b2;</italic>1 complex.</article-title>
                <source>J Biol Chem</source>
                <volume>285</volume>
                <fpage>17029</fpage>
                <lpage>37</lpage>
                <pub-id pub-id-type="pmid">20308061</pub-id>
              </element-citation>
            </ref>
            <ref id="ced.REF.watanabe.2002.478">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Watanabe</surname>
                    <given-names>Y</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kinoshita</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Yamada</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ohta</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kishino</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Matsumoto</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ishikawa</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Niikawa</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Yoshiura</surname>
                    <given-names>K</given-names>
                  </name>
                </person-group>
                <year>2002</year>
                <article-title>A catalog of 106 single-nucleotide polymorphisms (SNPs) and 11 other types of variations in genes for transforming growth factor-beta1 (TGF-beta1) and its signaling pathway.</article-title>
                <source>J Hum Genet</source>
                <volume>47</volume>
                <fpage>478</fpage>
                <lpage>83</lpage>
                <pub-id pub-id-type="pmid">12202987</pub-id>
              </element-citation>
            </ref>
            <ref id="ced.REF.yamada.2001.149">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Yamada</surname>
                    <given-names>Y</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Miyauchi</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Takagi</surname>
                    <given-names>Y</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tanaka</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mizuno</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Harada</surname>
                    <given-names>A</given-names>
                  </name>
                </person-group>
                <year>2001</year>
                <article-title>Association of the C-509--&#x0003e;T polymorphism, alone of in combination with the T869--&#x0003e;C polymorphism, of the transforming growth factor-beta1 gene with bone mineral density and genetic susceptibility to osteoporosis in Japanese women.</article-title>
                <source>J Mol Med</source>
                <volume>79</volume>
                <fpage>149</fpage>
                <lpage>56</lpage>
                <pub-id pub-id-type="pmid">11357939</pub-id>
              </element-citation>
            </ref>
            <ref id="ced.REF.ziv.2003.227">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Ziv</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kahn</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cauley</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Morin</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Saiz</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Browner</surname>
                    <given-names>W</given-names>
                  </name>
                </person-group>
                <year>2003</year>
                <article-title>No association between the TGF-beta 1 Leu10Pro polymorphism and osteoporosis among white women in the United States.</article-title>
                <source>Am J Med</source>
                <volume>114</volume>
                <fpage>227</fpage>
                <lpage>31</lpage>
                <pub-id pub-id-type="pmid">12637138</pub-id>
              </element-citation>
            </ref>
          </ref-list>
        </sec>
      </sec>
      <sec id="ced.Chapter_Notes">
        <title>Chapter Notes</title>
        <sec id="ced.Revision_History">
          <title>Revision History</title>
          <list list-type="bullet">
            <list-item>
              <p>5 March 2015 (me) Comprehensive update posted live</p>
            </list-item>
            <list-item>
              <p>6 December 2012 (me) Comprehensive update posted live</p>
            </list-item>
            <list-item>
              <p>1 June 2010 (me) Comprehensive update posted live</p>
            </list-item>
            <list-item>
              <p>16 August 2006 (me) Comprehensive update posted to live Web site </p>
            </list-item>
            <list-item>
              <p>25 June 2004 (me) Review posted to live Web site </p>
            </list-item>
            <list-item>
              <p>18 march 2004 (sw) Original submission </p>
            </list-item>
          </list>
        </sec>
      </sec>
    </body>
  </book-part>
</book-part-wrapper>
